GLOW 70
GL-W · 70 mg blend · daily, cycled
SCIENCE • STRENGTH • LONGEVITY
Before you draw anything. Every figure in this document assumes a 70 mg blend vial reconstituted with 3.0 mL of bacteriostatic water. Change either number and every unit measurement here changes with it. Confirm the milligram strength printed on your vial first.
RECONSTITUTION
| Parameter | Value |
|---|---|
| Vial | 70 mg total blend — 50 mg GHK-Cu, 10 mg TB-500, 10 mg BPC-157 |
| Ratio | 5 : 1 : 1, GHK-Cu dominant |
| Bacteriostatic water | 3.0 mL |
| Concentration | 23.3 mg/mL total blend |
| Conversion | 10 units = 2.33 mg total · 1 unit = 0.233 mg |
| Standard draw | 10 units daily |
| Site | Upper glute, subcutaneous |
| Vial coverage | 30 daily draws |
| Reconstituted storage | 2–8 °C (see stability note) |
| Lyophilized storage | −20 °C, 12+ months |
- Let the vial and the bacteriostatic water reach room temperature.
- Swab both stoppers with alcohol and let them dry.
- Draw the planned volume of bacteriostatic water into a sterile syringe.
- Aim the stream at the inside wall of the glass, never directly at the powder.
- Roll gently for 30 to 60 seconds until fully dissolved. Never shake — shaking damages the peptide.
- A faint blue or green tint is expected — that is the copper in GHK-Cu. Cloudiness or visible particulate is not.
- Label with product, concentration, and date, then refrigerate.
WHAT A 10-UNIT DRAW DELIVERS
| Component | Per 10-unit draw | Relative to standalone use |
|---|---|---|
| GHK-Cu | ~1.67 mg | Within the common 1–2 mg daily range |
| BPC-157 | ~0.33 mg | Within the common 0.25–0.5 mg daily range |
| TB-500 | ~0.33 mg | Well below standalone injury protocols (2–5 mg, 2x weekly) |
The blend is GHK-Cu dominant by weight, which orients it toward skin quality and general tissue remodeling. The TB-500 fraction is roughly a tenth of what a dedicated tendon or ligament protocol uses — where TB-500 needs to run high, separate vials are the better structure.
DOSING SCHEDULE
| Phase | Units | Amount | Frequency | Notes |
|---|---|---|---|---|
| On-cycle | 10 | 2.33 mg | Daily | One vial covers 30 consecutive days |
| Off-cycle | — | — | None | Match the length of the on-period |
Unlike the metabolic compounds, GLOW is not titrated. The draw stays at 10 units from the first day to the last — what changes is how long you run and how long you stop.
Cycle structure
| Approach | On-period | Off-period | Vials | Suited to |
|---|---|---|---|---|
| Short | 4 weeks | 4 weeks | 1 | A first run, or establishing tolerance |
| Standard | 30 days | 30 days | 1 | Skin quality and general remodeling |
| Extended | 60 days | 60 days | 2 | Longer recovery-focused runs |
The off-period is not optional. GHK-Cu adds copper systemically and copper accumulates with repeated exposure. That is what sets the cycle length for this blend, and why the off-period should match the on-period rather than being shortened to get back on sooner. Running through the off-period is the most common mistake made with this compound.
INJECTION NOTES
What to expect at the site
- Stinging or burning is expected, particularly across the first several sessions.
- Letting the vial reach room temperature before drawing reduces it noticeably.
- The reaction typically settles as the tissue adjusts over the first few injections.
- Reactions that worsen across the first week, spread outward, or turn sharply painful are a different signal from ordinary sting — stop and get it evaluated.
Stability across a vial
The three components do not degrade at the same rate. GHK-Cu and BPC-157 remain stable for the full 30 days refrigerated, but TB-500 falls off after one to two weeks. The back half of a 30-day vial is therefore effectively GHK-Cu and BPC-157 with a diminishing TB-500 fraction. Plan around that drop-off, or run a shorter reconstitution volume so each mix is used inside the TB-500 window.
CAUTIONS
- Active cancer or a strong cancer history. BPC-157 and TB-500 both promote angiogenesis, and that overlap is the primary caution raised in the literature.
- Active retinal vascular disease, or other conditions sensitive to angiogenic signaling.
- Wilson’s disease or any other copper-handling disorder — GHK-Cu adds copper systemically.
- Pregnancy or breastfeeding — no safety data exists.
- BPC-157 and TB-500 are prohibited by WADA and will test positive.
Supplies
- U-100 insulin syringes, 0.3 mL / 30-unit. Half-unit gradations matter at these draw volumes.
- Bacteriostatic water, 10 mL bottle.
- Alcohol prep pads and a sharps container.
Record keeping
Log the date, units drawn, and site for every injection, alongside any symptoms. This catches gradual dose drift, and if something does go wrong it identifies exactly which step it started on.